Responses
Clinical/translational cancer immunotherapy
Original research
Final results of urelumab, an anti-CD137 agonist monoclonal antibody, in combination with cetuximab or nivolumab in patients with advanced solid tumors
Compose a Response to This Article
Other responses
No responses have been published for this article.
